Trial
NCT02075021
Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
NYU Langone Health
Collaborators
Celgene Corporation
Condition
Relapsed or Refractory Multiple Myeloma
Intervention
Lenalidomide
Why stopped
PI left the institution
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-10-15